Literature DB >> 11384536

Candida dubliniensis candidemia in Australia.

D Marriott, M Laxton, J Harkness.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11384536      PMCID： PMC2631807          DOI： 10.3201/eid0703.010326

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN： 1080-6040            Impact factor:   6.883


× No keyword cloud information.
  10 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.

Authors:  Sarah F Gee; Sophie Joly; David R Soll; Jacques F G M Meis; Paul E Verweij; Itzhack Polacheck; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections.

Authors:  M D Moragues; M J Omaetxebarria; N Elguezabal; J Bikandi; G Quindós; D C Coleman; J Pontón
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

4.  Molecular epidemiology of Candida albicans and its closely related yeasts Candida dubliniensis and Candida africana.

Authors:  Orazio Romeo; Giuseppe Criseo
Journal:  J Clin Microbiol       Date:  2008-11-05       Impact factor: 5.948

5.  Candida dubliniensis infection, Singapore.

Authors:  Ai Ling Tan; Grace C Y Wang; Yoon Wan Chiu
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

6.  Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.

Authors:  Marçal Mariné; F Javier Pastor; Ismail H Sahand; José Pontón; Guillermo Quindós; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

7.  Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Authors:  A L Colombo; J Perfect; M DiNubile; K Bartizal; M Motyl; P Hicks; R Lupinacci; C Sable; N Kartsonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-23       Impact factor: 3.267

8.  Multilocus sequence typing reveals that the population structure of Candida dubliniensis is significantly less divergent than that of Candida albicans.

Authors:  Brenda A McManus; David C Coleman; Gary Moran; Emmanuelle Pinjon; Dorothée Diogo; Marie-Elisabeth Bougnoux; Silvia Borecká-Melkusova; Helena Bujdákova; Philip Murphy; Christophe d'Enfert; Derek J Sullivan
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

9.  Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.

Authors:  Ziauddin Khan; Suhail Ahmad; Leena Joseph; Rachel Chandy
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

10.  Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.

Authors:  Sebastian J van Hal; Damien Stark; John Harkness; Deborah Marriott
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.